基本信息
浏览量:15
职业迁徙
个人简介
Stuart Schreiber's lab studies the science of therapeutics. Researchers in his group rely on human biology to identify therapeutic targets that have been validated prior to testing in humans, and chemistry and chemical biology to discover small molecules that modulate the targets in ways required to provide relief or protection from disease.
Schreiber and his group members have discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. Their work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment.
In current research, the Schreiber lab is studying the mechanisms by which cancers resist therapies by exploring a vulnerability of a cell state that group members discovered as central to resistance of many cancers to many therapies. The lab is also studying a novel mechanism our brains use to maintain brain health, and therapeutic agents that enhance the brain-protective mechanism. Each of these studies is supported by efforts to discover small-molecule “binders” that alter functions of proteins by changing their interactomes and lifetimes. The lab is using modern methods of asymmetric synthesis to yield candidate binders bearing DNA barcodes.
Schreiber and his group members have discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. Their work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment.
In current research, the Schreiber lab is studying the mechanisms by which cancers resist therapies by exploring a vulnerability of a cell state that group members discovered as central to resistance of many cancers to many therapies. The lab is also studying a novel mechanism our brains use to maintain brain health, and therapeutic agents that enhance the brain-protective mechanism. Each of these studies is supported by efforts to discover small-molecule “binders” that alter functions of proteins by changing their interactomes and lifetimes. The lab is using modern methods of asymmetric synthesis to yield candidate binders bearing DNA barcodes.
研究兴趣
论文共 1 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn